JMJulio Morales-Esquivel

Julio Morales-Esquivel

*This is an algorithmically generated author record based on publicly available information.

Julio Morales-Esquivel has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Vaccine Candidate for Salmonella Control in Poultry

    by Suzette Curtello, Sehlule Vuma, Sachin Soodeen, Arlene Williams, Chandrashekar Unkal, Bijay Raj Pandit, Lisbeth Mache Suarez, Julio Morales Esquivel, Angel Justiz-Vaillant

    Salmonella infections in poultry represent a significant threat to public health and contribute to substantial economic losses within the agricultural sector. In response to these challenges, this study explored an innovative dual control strategy integrating the use of indigenous plant-based bacterial attenuation with targeted immunotherapy using egg yolk-derived immunoglobulin Y (IgY) antibodies. Garlic (Allium sativum) and onion (Allium cepa) extracts were employed to attenuate virulent strains of Salmonella enterica, resulting in a notable reduction in bacterial viability during in vitro assays. Following oral vaccination with the attenuated strains, chickens mounted a robust immune response, characterised by the production of high titres of anti-Salmonella IgY antibodies, as measured by ELISA. Functional assays demonstrated that these antibodies possessed strong agglutination activity against homologous Salmonella strains, highlighting their utility in passive immunisation protocols. Safety assessments confirmed the vaccine’s non-pathogenic profile, while immunogenicity trials showed consistent antibody production across vaccinated flocks. This dual modality—combining natural antimicrobial agents with specific IgY-based immunotherapy—offers a sustainable, low-cost alternative to antibiotics, with the potential to reduce zoonotic transmission, enhance poultry welfare, and support antimicrobial stewardship in animal husbandry.

  • Open Access

    Development of an Immunoglobulin Y (IgY)-Based Vaccine for Salmonella Control in Poultry

    by Angel Justiz-Vaillant, Sachin Soodeen, Julio Morales-Esquivel, Lisbeth Mache-Suarez, Suzette Curtello

    Salmonella infections in poultry represent a significant threat to public health and contribute to substantial economic losses within the agricultural sector. In response to these challenges, this study explored an innovative dual control strategy integrating the use of indigenous plant-based bacterial attenuation with targeted immunotherapy using egg yolk-derived immunoglobulin Y (IgY) antibodies. Garlic (Allium sativum) and onion (Allium cepa) extracts were employed to attenuate virulent strains of Salmonella enterica, resulting in a notable reduction in bacterial viability during in vitroassays. Following oral vaccination with the attenuated strains, chickens mounted a robust immune response, characterised by the production of high titres of anti-Salmonella IgY antibodies, as measured by ELISA. Functional assays demonstrated that these antibodies possessed strong agglutination activity against homologous Salmonella strains, highlighting their utility in passive immunisation protocols. Safety assessments confirmed the vaccine’s non-pathogenic profile, while immunogenicity trials showed consistent antibody production across vaccinated flocks. This dual modality—combining natural antimicrobial agents with specific IgY-based immunotherapy—offers a sustainable, low-cost alternative to antibiotics, with the potential to reduce zoonotic transmission, enhance poultry welfare, and support antimicrobial stewardship in animal husbandry.

  • Open Access

    Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved

    by Angel Justiz-Vaillant, Sachin Soodeen, Odalis Asin-Milan, Julio Morales-Esquivel, Rodolfo Arozarena-Fundora

    This review aims to explore the role of immunotherapeutic strategies—primarily intravenous immunoglobulin (IVIG), plasma exchange (PLEX), and selected immunomodulatory agents—in the treatment of neurological and psychiatric disorders with suspected or confirmed autoimmune mechanisms. A central focus is placed on understanding the immunopathology of these conditions through the identification and characterization of disease-associated autoantibodies. Disorders such as autoimmune encephalitis, myasthenia gravis, limbic epilepsy, neuropsychiatric systemic lupus erythematosus (NPSLE), and certain forms of schizophrenia have shown clinical responses to immunotherapy, suggesting an underlying autoimmune basis in a subset of patients. The review also highlights the diagnostic relevance of detecting autoantibodies targeting neuronal receptors, such as NMDA and AMPA receptors, or neuromuscular junction components, as biomarkers that guide therapeutic decisions. Furthermore, we synthesize findings from published randomized controlled trials (RCTs) that have validated the efficacy of IVIG and PLEX in specific diseases, such as Guillain–Barré syndrome, and myasthenia gravis. Emerging clinical evidence supports expanding these treatments to other conditions where autoimmunity is implicated. By integrating immunological insights with clinical trial data, this review offers a comprehensive perspective on how immunotherapies may be tailored to target autoimmune contributors to neuropsychiatric disease.


  • Open Access

    Antibody-Drug Conjugates (ADCs) and Indications in Autoimmune Disorders

    by Angel Justiz-Vaillant, Sachin Soodeen, Julio Morales-Esquivel, Chandrashekhar Unakal

    Antibody-drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. These engineered molecules are designed to selectively deliver cytotoxic agents to specific cells, thereby reducing off-target toxicity and enhancing therapeutic efficacy. In oncology, ADCs have already demonstrated significant clinical success, particularly in the treatment of hematological malignancies and solid tumors. Agents such as trastuzumab emtansine and brentuximab vedotin exemplify how ADCs can effectively target cancer cells while limiting damage to healthy tissues. This review comprehensively explores key aspects of the use of ADCs in autoimmune disorders—an evolving field in immunotherapy.

  • Open Access

    Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved

    by Angel Justiz-Vaillant, Sachin Soodeen, Odalis Asin-Milan, Julio Morales-Esquivel, Rodolfo Arrozarena-Fundora

    Glutamatergic pathway abnormalities are increasingly recognised as central to various neuropsychiatric disorders, including autoimmune encephalitis, schizophrenia, and epilepsy, where autoantibodies targeting NMDA, AMPA, and GluR3 receptors are frequently implicated. In systemic lupus erythematosus (SLE), these autoantibodies, along with pro-inflammatory cytokines, are linked to neurocognitive impairments and mood disturbances. Elevated cytokine levels similarly contribute to the pathophysiology of epilepsy and other neurological conditions. Immunotherapies such as intravenous immunoglobulin (IVIG) have shown efficacy in mitigating some autoimmune neurological symptoms, though they offer limited benefit in disorders like amyotrophic lateral sclerosis and autism. Moreover, disruption of the blood-brain barrier—as observed in diseases such as multiple sclerosis and Guillain-Barré syndrome—permits pathogenic immune elements to infiltrate the central nervous system, exacerbating neuroinflammation. These insights highlight the urgent need for precise immunological screening and personalised treatment strategies to address immune-related neurological dysfunctions.

  • Open Access

    Development of an IgY-Based Vaccine for Salmonella Control in Poultry

    by Angel Justiz-Vaillant, Sachin Soodeen, Patrick E. Akpaka, Julio Morales-Esquivel, Maudlin Francis, Lisbeth Mache-Suarez, Kadia Kallap, Rodolfo Arozarena-Fundora, Safiya Greaves, Hellen Asemota, et al.

    Background: Salmonella infections in poultry pose significant public health and economic challenges due to contamination of meat and eggs and the rise of antimicrobial resistance. Innovative control strategies are needed to reduce Salmonella in poultry flocks. Methods: We explored a novel approach integrating a live attenuated Salmonella vaccine and IgY antibody therapy. Several indigenous plant extracts were screened as natural attenuating agents for Salmonella. The most effective (garlic and onion extracts) were used to attenuate a cocktail of five wild-type Salmonella serovars (S. Montevideo, S. Yeerongpilly, S. Augustenborg, S. Kentucky, and S. Typhimurium). Chickens were immunized with the plant-attenuated Salmonella vaccine, and the resulting egg yolk IgY antibodies were harvested. We assessed in vitro bacterial growth inhibition, vaccine safety and immunogenicity (via ELISA for anti-Salmonella IgY), and performed statistical analyses to evaluate significance. Results: Garlic and onion extracts markedly inhibited Salmonella growth in vitro, yielding significantly smaller colonies (1.0–1.5 mm) compared to untreated controls (4.1 mm, p < 0.05). Combining garlic and onion achieved complete inhibition (no visible colonies), indicating a potent attenuation effect. Plant-extract attenuation did not compromise immunogenicity: chickens vaccinated with the attenuated strains developed high titers of anti-Salmonella IgY, with ELISA optical density values (~1.2 at 1:500 dilution) far above the negative cut-off (0.35). The IgY antibodies showed strong agglutination of Salmonella and are expected to confer passive protection. Recent studies corroborate that orally administered anti-Salmonella IgY can reduce intestinal colonization and shedding in chickens. Conclusion: This study demonstrates a feasible, cost-effective strategy for Salmonella control in poultry by using indigenous plant extracts to create a live attenuated vaccine and harnessing resultant IgY antibodies for therapy.